Kristina Torfgaard
CEO
Replay available
IRLAB Therapeutics AB (publ) (IRLAB_A) Q3 2024 Earnings Call
IRLAB Therapeutics AB (publ) (STO: IRLAB_A) Q3 2024 earnings conference call, held 2024-10-30. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Niklas Waters
Executive Vice President R&D
Viktor Sivic
CFO
Fredrik Thur
Equity Analyst, Redeye
Alexander Kremer
Equity Analyst, ABG Sundal Collier
Aaron Atker
Equity Analyst, Edison Group
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Irlab Therapeutics Ab Class A.
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:05.656 Welcome to yet an inspiring quarterly presentation by research company 00:00:05.656 -- 00:00:07.656 iLab. 00:00:07.998 -- 00:00:13.403 Presenting today will be newly appointed CEO Kristina Torfgaard, 00:00:13.403 -- 00:00:18.667 Executive Vice President R&D Niklas Waters and CFO 00:00:18.667 -- 00:00:21.289 Viktor Sivic. 00:00:21.289 -- 00:00:28.034 After the presentation, there will be a Q&A with participating equity analysts. 00:00:28.035 -- 00:00:31.377 Hello and welcome, Kristina. 00:00:31.773 -- 00:00:33.695 Hello, good morning. Thank you. 00:00:33.695 -- 00:00:38.481 Good morning. You came on board Aerolab 1st of August. 00:00:38.481 -- 00:00:44.087 Could you please tell us a bit how this first few months have been with the company? 00:00:44.087 -- 00:00:49.714 Yes, so this is the first quarter for me as the CEO of Aerolab 00:00:49.714 -- 00:00:55.841 and it has been eventful and I have got quite a lot of very 00:00:55.841 -- 00:00:59.701 good insight in the company and it's a great company. 00:00:59.701 -- 00:01:05.226 And I would say that everything goes back to really the organization. 00:01:05.226 -- 00:01:07.508 It's a very experienced 00:01:07.508 -- 00:01:12.633 and dedicated team behind the company. And I'm very, 00:01:12.633 -- 00:01:17.858 very honored and it's great to take the lead and 00:01:17.858 -- 00:01:23.383 leading the company now where we have such a very important mission to develop new 00:01:23.383 -- 00:01:29.384 innovative treatments for people suffering from Parkinson's. 00:01:29.384 -- 00:01:34.451 And I'm very, very happy to be part of this team also and to be part of 00:01:34.451 -- 00:01:40.320 this journey that we are doing, because what we are really aiming to is to 00:01:40.320 -- 00:01:46.987 ...